KINJO Hidetoshi

写真a

Title

Assistant Professor

Researcher Number(JSPS Kakenhi)

00636417

Date of Birth

1984

Mail Address

E-mail address

To the head of this page.▲

Current Affiliation Organization 【 display / non-display 】

  • Duty   University of the Ryukyus   Hospital   Assistant Professor  

To the head of this page.▲

University 【 display / non-display 】

  • 　
    -
    2009.03

    University of the Ryukyus   Faculty of Medicine   Graduated

To the head of this page.▲

External Career 【 display / non-display 】

  • 2014.04
    -
    2015.03

     

  • 2015.04
    -
    2016.03

     

  • 2016.04
    　
    　

     

To the head of this page.▲

Research Areas 【 display / non-display 】

  • Life Science / Otorhinolaryngology

To the head of this page.▲

Acquisition of a qualification 【 display / non-display 】

  • Doctor

To the head of this page.▲

Published Papers 【 display / non-display 】

  • Two cases of favorable response to combination therapy of photoimmunotherapy after administration of immune checkpoint inhibitors for recurrent head and neck cancer

    Hayashi Yoshikazu, Hirakawa Hitoshi, Kinjyo Hidetoshi, Agena Shinya, Maeda Hiroyuki, Suzuki Mikio

    JOURNAL OF JAPAN SOCIETY FOR HEAD AND NECK SURGERY ( JAPAN SOCIETY FOR HEAD AND NECK SURGERY )  34 ( 3 ) 307 - 311   2025

    Type of publication: Research paper (scientific journal)

    　View Summary

    Photoimmunotherapy (PIT) is a treatment for unresectable locally advanced head and neck cancer or locally recurrent head and neck cancer that has become difficult to treat after standard therapies. PIT was approved in Japan in January 2021. PIT enhances the immune response and, when combined with immune checkpoint inhibitors (ICIs), its effectiveness is amplified. This study presents two cases where PIT was highly effective after ICI treatment. The first case was a 69-year-old male with oropharyngeal squamous cell carcinoma and the second case was a 66-year-old male with recurrent anterior neck cancer. In both cases, complete response (CR) was maintained after one course of PIT for the residual disease following ICI. The combination of PIT and ICIs showed a synergistic effect. Although there is no consensus on the optimal timing for conducting PIT, these results suggest that PIT following ICI treatment may be a highly effective option.

  • Feasibility of Near-infrared Photoimmunotherapy Combined With Immune Checkpoint Inhibitor Therapy in Unresectable Head and Neck Cancer

    HITOSHI HIRAKAWA, TARO IKEGAMI, HIDETOSHI KINJYO, YOSHIKAZU HAYASHI, SHINYA AGENA, TERUYUKI HIGA, SHUNSUKE KONDO, MASATOMO TOYAMA, HIROYUKI MAEDA, MIKIO SUZUKI

    Anticancer Research ( Anticancer Research USA Inc. )  44 ( 9 ) 3907 - 3912   2024.08 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

    • Access this article
      DOI Open Access

  • Biomarkers for Predicting Anti-Programmed Cell Death-1 Antibody Treatment Effects in Head and Neck Cancer.

    Katsunori Tanaka, Hitoshi Hirakawa, Mikio Suzuki, Teruyuki Higa, Shinya Agena, Narumi Hasegawa, Junko Kawakami, Masatomo Toyama, Tomoyo Higa, Hidetoshi Kinjyo, Norimoto Kise, Shunsuke Kondo, Hiroyuki Maeda, Taro Ikegami

    Current oncology (Toronto, Ont.)   30 ( 6 ) 5409 - 5424   2023.06 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

    　View Summary

    In recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC), survival outcomes are significantly better in patients who receive anti-programmed cell death-1 (PD-1) monoclonal antibody therapy than in those who receive standard therapy. However, there is no established biomarker that can predict the anti-PD-1 antibody treatment effect and immune-related adverse events (irAEs) in these patients. This study investigated the inflammatory and nutritional status in 42 patients with R/M-HNSCC and programmed cell death ligand-1 (PD-L1) polymorphisms (rs4143815 and rs2282055) in 35 of the 42 patients. The 1- and 2-year overall survival was 59.5% and 28.6%, respectively; the 1- and 2-year first progression-free survival was 19.0% and 9.5%, respectively, and the respective second progression-free survival was 50% and 27.8%. Performance status and inflammatory and nutritional status (assessed by the geriatric nutritional risk index, modified Glasgow prognostic score, and prognostic nutritional index) were identified as significant indicators of survival outcomes in multivariate analysis. Patients with ancestral alleles in PD-L1 polymorphisms had less frequent irAEs. Performance status and inflammatory and nutritional status before treatment were closely related to survival outcomes after PD-1 therapy. These indicators can be calculated using routine laboratory data. PD-L1 polymorphisms may be biomarkers for predicting irAEs in patients receiving anti-PD-1 therapy.

  • Human papillomavirus infection and EGFR exon 20 insertions in sinonasal inverted papilloma and squamous cell carcinoma

    Hitoshi Hirakawa, Taro Ikegami, Norimoto Kise, Hidetoshi Kinjyo, Shunsuke Kondo, Shinya Agena, Narumi Hasegawa, Junko Kawakami, Hiroyuki, Maeda, Mikio Suzuki

    Journal of Personalized Medicine   13 ( 4 ) 657   2023.04 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

    • Access this article
      DOI Open Access

  • p16 Overexpression in Sinonasal Squamous Cell Carcinoma: Association with Human Papillomavirus and Prediction of Survival Outcomes

    Hitoshi Hirakawa , Taro Ikegami, Mikio Suzuki

    Journal of Clinical Medicine     2023 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

display all >>

To the head of this page.▲

Grant-in-Aid for Scientific Research 【 display / non-display 】

  • Grant-in-Aid for Scientific Research(S)

    Project Year: 2024.04  -  2029.03 

  • Grant-in-Aid for Young Scientists(A)

    Project Year: 2018.04  -  2022.03 

To the head of this page.▲